High-grade glioma in elderly patients: can the oncogeriatrician help?
Authors Tabouret E, Tassy L, Chinot O, Crétel E, Retornaz F, Rousseau F
Received 27 July 2013
Accepted for publication 9 October 2013
Published 6 December 2013 Volume 2013:8 Pages 1617—1624
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 2
Emeline Tabouret,1 Louis Tassy,2 Olivier Chinot,1 ElodieCrétel,3 Frederique Retornaz,4 Frederique Rousseau5
1Department of Neuro-oncology, Timone Hospital, Marseille, France; 2Department of Medical Oncology, Centre Léon Bérard, Lyon, France; 3Transveral Oncogeriatric Unit, University Hospital Timone, Marseille, France; 4Departmental Gerontologic Center, Marseille, France; 5Department of Medical Oncology, Institut Paoli Calmettes, Marseille, France
Abstract: Gliomas are the most frequent primary brain tumors in adults. As the population ages in Western countries, the number of people being diagnosed with glioblastoma is expected to increase. Clinical management of elderly patients with primary brain tumors is difficult, owing to multiple comorbidities, polypharmacy, decreased tolerance to chemotherapy, and an increased risk of radiation-induced neurotoxicity. A few specific randomized studies have shown a benefit for radiotherapy in elderly patients with good performance status. For patients with poor performance status, chemotherapy (temozolomide) has been shown to be associated with prolonged duration of response. Patients with methylated O6-alkylguanine deoxyribonucleic acid alkyltransferase promoter seem to have better outcomes. Oncogeriatrics proposes the geriatric evaluation of elderly patients to improve therapeutic choices and optimize the management of treatment toxicities and comorbidities.
Keywords: brain tumor, older cancer patient, chemotherapy toxicity, oncogeriatric charter
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF]